Media List

• Notice of Amendments to SK Biopharmaceuticals Co., Ltd. Privacy Policy and Consent Form

  Events 2025.06.17

  Notice of Amendments to SK Biopharmaceuticals Co., Ltd. Privacy Policy and Consent Form Thank you for visiting the SK Biopharmaceuticals website. We would like to inform you th....

• 

  SK Biopharmaceuticals, ProEn Therapeutics Join Hands for Radiopharmaceuticals

  Press Release 2024.12.17

  SK Biopharmaceuticals Inks Research Collaboration Agreement with ProEn Therapeutics Further Accelerating Expansion of Oncology Research and Pipeline for Global Competitiven....

• 

  SK Biopharmaceuticals, KIRAMS Seal Collaborative Research Agreement

  Press Release 2024.11.19

  SK Biopharmaceuticals Seals 1st Actinium-225-Based Collaborative Research Agreement with Korea Institute of Radiological and Medical Sciences as Steps Toward Becoming Global Radio....

• SK Biopharmaceuticals’ Partner Eurofarma Submits Prioritized NDA for Cenobamate in Brazil

  Press Release 2024.10.08

  [Translated ver.]   SK Biopharmaceuticals’ Partner Eurofarma Submits Prioritized NDA for Cenobamate in Brazil   Korea and Brazil, Oct. 8, 2024 – ....

• 

  SK Biopharmaceuticals, Full-Life Technologies Enter Licensing Agreement

  Press Release 2024.07.17

  SK Biopharmaceuticals, Full-Life Technologies Enter Licensing Agreement for Novel Therapeutic Targeting Multiple Solid Tumors SK Biopharmaceuticals, Full-Life Technologies se....

• 

  Mobilizing at 2024 Bio

  Press Release 2024.06.03

    Mobilizing at 2024 Bio SK Biopharmaceuticals has mobilized its U.S. subsidiaries SK Life Science, Inc. and SK Life Science Labs to promote their busines....

• 

  SK Biopharmaceuticals Posts 2024 Q1 Turnaround, Setting the Stage for Annual Profit

  Press Release 2024.05.09

  SK Biopharmaceuticals Posts 2024 Q1 Turnaround, Setting the Stage for Annual Profit   Sales reach KRW 114 billion, operating profit hits KRW 10.3 billion XCOPRI®....

• 

  100,000 Patients Globally Have Been Treated with Cenobamate

  Press Release 2024.03.12

  SK Biopharmaceuticals Announces 100,000 Patients Globally Have Been Treated with Cenobamate Through Sales of XCOPRI® and ONTOZRY® in the U.S., Europe, Israel, and Canada ....

• 

  Ready for 2nd Take Off

  Press Release 2024.02.16

    Ready for 2nd Take Off SK Biopharmaceuticals CEO Donghoon Lee presents its 2024 strategy at SK Life Science's annual National Sales Meeting in Tampa, Florida,....

• 

  Reaffirming Vision

  Press Release 2024.01.09

    Reaffirming Vision Donghoon Lee, CEO of SK Biopharmaceuticals, gives a presentation to global investors at J.P. Morgan Healthcare Conference in San Fran....